Diplomat Pharmacy, Inc. (DPLO) Position Increased by Voya Investment Management LLC

Voya Investment Management LLC boosted its holdings in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 10.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,641 shares of the company’s stock after purchasing an additional 2,040 shares during the quarter. Voya Investment Management LLC’s holdings in Diplomat Pharmacy were worth $320,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of DPLO. Parametric Portfolio Associates LLC raised its stake in Diplomat Pharmacy by 114.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 55,899 shares of the company’s stock valued at $892,000 after purchasing an additional 29,819 shares during the period. JPMorgan Chase & Co. raised its stake in Diplomat Pharmacy by 73.1% during the 1st quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after purchasing an additional 3,056 shares during the period. Principal Financial Group Inc. raised its stake in Diplomat Pharmacy by 5.0% during the 1st quarter. Principal Financial Group Inc. now owns 329,853 shares of the company’s stock valued at $5,261,000 after purchasing an additional 15,576 shares during the period. Teachers Advisors LLC raised its stake in Diplomat Pharmacy by 112.8% during the 1st quarter. Teachers Advisors LLC now owns 279,303 shares of the company’s stock valued at $4,455,000 after purchasing an additional 148,060 shares during the period. Finally, TIAA CREF Investment Management LLC raised its stake in Diplomat Pharmacy by 55.3% during the 1st quarter. TIAA CREF Investment Management LLC now owns 372,753 shares of the company’s stock valued at $5,945,000 after purchasing an additional 132,783 shares during the period. 66.51% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Stock Observer and is the property of of Stock Observer. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.thestockobserver.com/2017/11/14/diplomat-pharmacy-inc-dplo-position-increased-by-voya-investment-management-llc.html.

Shares of Diplomat Pharmacy, Inc. (DPLO) opened at $19.80 on Tuesday. The company has a quick ratio of 0.82, a current ratio of 1.34 and a debt-to-equity ratio of 0.18. Diplomat Pharmacy, Inc. has a 12 month low of $12.25 and a 12 month high of $21.99. The stock has a market capitalization of $1,354.03, a P/E ratio of 25.53, a price-to-earnings-growth ratio of 3.54 and a beta of 0.74.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the company posted $0.21 EPS. The company’s revenue was down 4.8% compared to the same quarter last year. sell-side analysts expect that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current year.

Several brokerages recently issued reports on DPLO. TheStreet raised Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. Mizuho set a $16.00 target price on Diplomat Pharmacy and gave the company a “hold” rating in a research note on Tuesday, October 24th. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Needham & Company LLC lifted their target price on Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Finally, BidaskClub downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $20.06.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply